Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

A man who fainted in the Oval Office last week was a patient of a weight-loss drug company, according to reports.

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...

Under the agreement, the Danish drugmaker will sell Poviztra 2.4 milligram (mg) semaglutide injection in India as a separate ...

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand ...

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...